Compare CRSP & SON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | SON |
|---|---|---|
| Founded | 2013 | 1899 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | 2016 | 2014 |
| Metric | CRSP | SON |
|---|---|---|
| Price | $60.11 | $56.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $70.00 | $63.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-15-2026 | 05-20-2026 |
| Dividend Yield | N/A | ★ 3.79% |
| EPS Growth | N/A | ★ 510.30 |
| EPS | N/A | ★ 10.07 |
| Revenue | $289,590,000.00 | ★ $7,518,753,000.00 |
| Revenue This Year | $1,603.19 | $0.27 |
| Revenue Next Year | $78.75 | $1.94 |
| P/E Ratio | ★ N/A | $8.28 |
| Revenue Growth | ★ 9169.85 | 41.72 |
| 52 Week Low | $30.06 | $38.65 |
| 52 Week High | $78.48 | $58.44 |
| Indicator | CRSP | SON |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 69.09 |
| Support Level | $58.40 | $43.81 |
| Resistance Level | $60.40 | $58.44 |
| Average True Range (ATR) | 3.03 | 1.53 |
| MACD | 1.16 | 0.07 |
| Stochastic Oscillator | 86.78 | 74.07 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.